ESPR - Esperion closes down 16% following BofA downgrade
2024-06-20 16:10:36 ET
More on Esperion Therapeutics
- Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
- Esperion's late stage trial of high cholesterol treatment met main goal
- Esperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook
- Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript
- Esperion Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation